PA8755801A1 - Antagonistas del receptor de progesterona - Google Patents

Antagonistas del receptor de progesterona

Info

Publication number
PA8755801A1
PA8755801A1 PA20078755801A PA8755801A PA8755801A1 PA 8755801 A1 PA8755801 A1 PA 8755801A1 PA 20078755801 A PA20078755801 A PA 20078755801A PA 8755801 A PA8755801 A PA 8755801A PA 8755801 A1 PA8755801 A1 PA 8755801A1
Authority
PA
Panama
Prior art keywords
progesterone
antagonists
receiver antagonists
progesterone receiver
general formula
Prior art date
Application number
PA20078755801A
Other languages
English (en)
Spanish (es)
Inventor
Cleve Arwed
Fuhrmann Ulrike
Schmidt Anja
Petrov Orlin
Garke Gunnar
Pruehs Stefan
Brudny-Kloeppel Margarete
Rottmann Antje
Hasselmann Rainer
Schultze-Mosgau Marcus
Moller Carsten
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8755801A1 publication Critical patent/PA8755801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PA20078755801A 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona PA8755801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten

Publications (1)

Publication Number Publication Date
PA8755801A1 true PA8755801A1 (es) 2009-08-26

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20078755801A PA8755801A1 (es) 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona

Country Status (40)

Country Link
US (1) US8053426B2 (https=)
EP (1) EP2081951B1 (https=)
JP (1) JP5260537B2 (https=)
KR (1) KR101494914B1 (https=)
CN (1) CN101541823B (https=)
AR (1) AR063813A1 (https=)
AT (1) ATE465169T1 (https=)
AU (1) AU2007321848B2 (https=)
BR (1) BRPI0718409A2 (https=)
CA (1) CA2669767C (https=)
CL (1) CL2007003266A1 (https=)
CO (1) CO6180443A2 (https=)
CY (1) CY1110671T1 (https=)
DE (2) DE102006054535A1 (https=)
DK (1) DK2081951T3 (https=)
EA (1) EA017038B1 (https=)
EC (1) ECSP099337A (https=)
ES (1) ES2343915T3 (https=)
GT (1) GT200900128A (https=)
HN (1) HN2009000997A (https=)
HR (1) HRP20100366T1 (https=)
IL (1) IL198650A (https=)
JO (1) JO2672B1 (https=)
MA (1) MA30990B1 (https=)
MX (1) MX2009005212A (https=)
NO (1) NO20092284L (https=)
NZ (1) NZ576927A (https=)
PA (1) PA8755801A1 (https=)
PE (1) PE20081409A1 (https=)
PL (1) PL2081951T3 (https=)
PT (1) PT2081951E (https=)
RS (1) RS51369B (https=)
SI (1) SI2081951T1 (https=)
SV (1) SV2009003260A (https=)
TN (1) TN2009000185A1 (https=)
TW (1) TW200831109A (https=)
UA (1) UA98312C2 (https=)
UY (1) UY30718A1 (https=)
WO (1) WO2008058767A1 (https=)
ZA (1) ZA200904150B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
US20170266204A1 (en) * 2016-03-21 2017-09-21 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
ES2218556T3 (es) 1994-11-22 2004-11-16 Balance Pharmaceuticals, Inc. Metodos de contracepcion.
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
HRP20030386A2 (en) * 2000-10-18 2005-04-30 Schering Aktiengesellschaft Inhibition of the growth factor dependency of tumor cells
US20020143000A1 (en) 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE10221034A1 (de) 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2252670T3 (es) 2002-05-03 2006-05-16 Schering Ag Esteroides con fluoroalquilo en 17a y benzaldoxima en 11beta, procedimiento para su preparacion, formulaciones farmaceuticas que contienen estos esteroides, asi como su utilizacion para la produccion de medicamentos.
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
EA200900635A1 (ru) 2009-12-30
WO2008058767A1 (en) 2008-05-22
DE102006054535A1 (de) 2008-05-21
CL2007003266A1 (es) 2008-07-04
CA2669767A1 (en) 2008-05-22
ATE465169T1 (de) 2010-05-15
PL2081951T3 (pl) 2010-09-30
ES2343915T3 (es) 2010-08-12
KR101494914B1 (ko) 2015-02-23
SV2009003260A (es) 2009-12-14
JO2672B1 (en) 2012-06-17
US8053426B2 (en) 2011-11-08
NZ576927A (en) 2012-01-12
CA2669767C (en) 2014-04-01
JP5260537B2 (ja) 2013-08-14
EA017038B1 (ru) 2012-09-28
RS51369B (sr) 2011-02-28
AU2007321848A1 (en) 2008-05-22
DE602007006040D1 (de) 2010-06-02
UA98312C2 (en) 2012-05-10
ECSP099337A (es) 2009-06-30
CO6180443A2 (es) 2010-07-19
KR20090079995A (ko) 2009-07-22
HN2009000997A (es) 2011-10-19
HRP20100366T1 (hr) 2010-07-31
PE20081409A1 (es) 2008-12-05
IL198650A0 (en) 2010-02-17
AR063813A1 (es) 2009-02-18
EP2081951A1 (en) 2009-07-29
TW200831109A (en) 2008-08-01
SI2081951T1 (sl) 2010-08-31
DK2081951T3 (da) 2010-08-09
CY1110671T1 (el) 2015-06-10
CN101541823B (zh) 2012-10-03
JP2010509386A (ja) 2010-03-25
GT200900128A (es) 2012-02-01
MX2009005212A (es) 2009-05-27
NO20092284L (no) 2009-08-13
UY30718A1 (es) 2008-07-03
AU2007321848B2 (en) 2013-09-19
IL198650A (en) 2012-05-31
HK1136302A1 (en) 2010-06-25
MA30990B1 (fr) 2009-12-01
CN101541823A (zh) 2009-09-23
PT2081951E (pt) 2010-07-01
ZA200904150B (en) 2010-11-24
EP2081951B1 (en) 2010-04-21
BRPI0718409A2 (pt) 2013-12-17
TN2009000185A1 (en) 2010-10-18
US20080200440A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
PA8755801A1 (es) Antagonistas del receptor de progesterona
CU23818A3 (es) Antagonistas del receptor de progesterona
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
ATE469895T1 (de) Cgrp-rezeptorantagonisten
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
CR20120333A (es) Isoquinolinonas y quinazolinonas substituidas.
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
DOP2012000148A (es) Combinaciones de un antagonista de los receptores muscarinicos y un agonista del adreno-receptor beta-2
PA8854001A1 (es) Compuestos novedosos como ligandos de receptores de canabinoides
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
JOP20180077A1 (ar) تركيبات وطرق لحمض صفراوي تخليقي
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
CO6241154A2 (es) "compuestos novedosos con accion agonista o antagonista del receptor 1 vainilloide 1 (vr1/trpv1)\"
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
BRPI0916657A2 (pt) pirrolidin-3-ilmetil-amina como antagonistas de orexina
MX2012005155A (es) Compuestos de quinazolina.
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.